Foster Wheeler AG
(NASDAQ:FWLT) stock increased 2.34% to $18.34 after the company posted
second-quarter net income of $30.9 million or $0.29 per share, as against $63.3
million or $0.52 per share reported a year ago. Operating revenues for the
quarter declined to $943.03 million from last year's $1.18 billion. Analysts
polled by Thomson Reuters expected the company to report earnings of $0.43 per
share on revenues of $1.13 billion for the quarter.
Get Free Trend Analysis
on FWLT
The Goodyear Tire &
Rubber Company (NYSE:GT) stock surged 10.13% to $11.42 after the company
reported second quarter net income of $86 million, or $0.33 per diluted share,
as compared to $40 million, or $0.16 per diluted share, in the year ago period.
Total Sales declined to $5.15 billion from $5.62 billion reported for the same
quarter in the previous year. Analysts expected the company to report earnings
of $45 per share on revenues of $5.74 billion for the quarter.
HCP, Inc. (NYSE:HCP)
stock declined 0.06% to $47.10 after the company reported second quarter funds
from operations, or FFO, of $293.62 million or $0.69 per share, as compared to
$317.91 million or $0.78 per share in the same quarter last year. Net income
for the quarter fell year-over-year to $201.47 million or $0.48 per share from
$222.99 per share or $0.55 per share. Total revenues decreased to $464.44
million from $488.13 million in the prior year. Analysts expected the company
to report earnings of $0.68 per share on revenues of $461.51 million for the
quarter.
Get Free Trend Analysis on HCP
Louisiana-Pacific
Corporation (NYSE:LPX) stock fell 6.99% to $10.24 after the company reported
second-quarter net loss of $37.3 million or $0.27 per share, as compared to a
loss of $35.5 million or $0.27 per share in the same quarter last year. Net
sales rose to $427.8 million from $362.4 million in the prior year quarter.
Analysts expected the company to report earnings of $0.05 per share on revenue
estimate of $419.29 million for the quarter.
Pfizer Inc. (NYSE:PFE)
stock increased 2.23% to $24.24 after the company announced top-line results
from ORAL Start (A3921069), a Phase 3 study of the investigational agent
tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of
adults with moderate-to-severe active rheumatoid arthritis (RA).
No comments:
Post a Comment